All In Biotech

Drug Trial Radar · NCT03739112

Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

A Randomized, Observer-blind, Active Comparator-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-derived Quadrivalent VLP Influenza Vaccine in Adults 65 Years of Age and Older

Last checked: Nov 20, 2026Latest source record: Jun 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 12,794 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

12,794

Actual

Start

Sep 18, 2018

Primary completion

May 17, 2019

Study completion Jul 16, 2019

Sponsor

Lead sponsor
MedicagoIndustry
Sponsor type
Industry
First posted
Nov 13, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 3 study was intended to assess the relative efficacy of the Quadrivalent VLP Influenza Vaccine during the 2018-2019 influenza season compared to a licensed vaccine in elderly adults 65 years of age and older. One dose of VLP Influenza Vaccine (30 μg/strain) or of Comparator (15 μg/strain) was to be administered to 12,738 participants.

Conditions

  • Virus Diseases
  • RNA Virus Infections
  • Respiratory Tract Diseases
  • Respiratory Tract Infections

Interventions

  • Quadrivalent VLP VaccineBiological

    Single dose of a 30 µg/strain of Quadrivalent VLP Vaccine

  • Fluarix Quadrivalent® Comparator VaccineBiological

    Single dose of a 15 μg/strain of Fluarix Quadrivalent® Comparator Vaccine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Occurrences of Protocol-Defined Influenza-Like Illness (ILI) Due to Any Laboratory-Confirmed Influenza StrainsTime frame: Day 14 (post-vaccination) up to ~9 months

Locations

104 sites in 5 countries. Site status is shown where the registry gives one.

  • (Site 225) Coastal Clinical Research

    Mobile, Alabama

  • (Site 201) Clinical Research Consortium

    Tempe, Arizona

  • (Site 213) Advanced Clinical Research

    Banning, California

  • (Site 246) Paradigm Clinical Research / Pharmaseek

    Redding, California

  • (Site 212) Benckmark Research

    Sacramento, California

  • (Site 244) Paradigm Clinical Research Center Inc

    San Diego, California

  • (Site 242) Paradigm Clinical Research Centers Inc

    Wheat Ridge, Colorado

  • (Site 239) Alliance for Multispeciality Research

    Coral Gables, Florida

  • (Site 222) Research Centers of America

    Hollywood, Florida

  • (Site 221) St-Johns Center for Clinical Research

    Ponte Vedra, Florida

  • (Site 231) QPS-MRA LLC

    South Miami, Florida

  • (Site 251) Meridian Clinical Research

    Richmond Hill, Georgia

  • (Site 240) Meridian Clinical Research LLC

    Savannah, Georgia

  • (Site 223) Clinical Research Atlanta

    Stockbridge, Georgia

  • (Site 249) Advanced Clinical Research

    Meridian, Idaho

  • (Site 219) Heartland Research Associates LLC

    Augusta, Kansas

  • (Site 234) Heartland Research Associates LLC

    Newton, Kansas

  • (Site 215) Heartland Research Associates LLC

    Wichita, Kansas

  • (Site 235) Heartland Research Associates LLC

    Wichita, Kansas

  • (Site 241) Central Kentucky Reserach Associates

    Lexington, Kentucky

  • (Site 203) Benchmark Research

    Metairie, Louisiana

  • (Site 227) Sundande Clinical Research

    St Louis, Missouri

  • (Site 226) Meridian Clinical Research LLC

    Norfolk, Nebraska

  • (Site 211) Meridian Clinical Research

    Omaha, Nebraska

  • (Site 209) United Medical Associates

    Binghamton, New York

  • (Site 217) Regional Clinical Research inc

    Endwell, New York

  • (Site 237) PMG Research of Cary LLC

    Cary, North Carolina

  • (Site 230) PMG Research of Charlotte LLC

    Charlotte, North Carolina

  • (Site 205) PMG Research of Rocky Mount LLC

    Rocky Mount, North Carolina

  • (Site 236) PMG Research

    Statesville, North Carolina

  • (Site 228) Research of Winston-Salem

    Winston-Salem, North Carolina

  • (Site 233) Sterling Research Group

    Cincinnati, Ohio

  • (Site 208) Sterling Research Group

    Cincinnati, Ohio

  • (Site 245) Rapid Medical Research

    Cleveland, Ohio

  • (Site 202) Aventiv Research Inc

    Columbus, Ohio

  • (Site 207) Lynn Institute of Norman

    Norman, Oklahoma

  • (Site 238) Tekton Research

    Oklahoma City, Oklahoma

  • (Site 216) PMG Research of Charleston LLC

    Mt. Pleasant, South Carolina

  • (Site 248) Coastal Carolina Research Center

    Mt. Pleasant, South Carolina

  • (Site 201) Meridian Clinical Research

    Dakota Dunes, South Dakota

Showing 40 of 104 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.